QURE
uniQure NV
NASDAQ · Healthcare · Biotechnology · NL
$23.03
−3.52%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$24.03
From 52W high−54.89%
Volume2.49M
Market cap$1.60B
P/E (TTM)—
P/S (TTM)85.6x
Div yield—
Key dataNov 4, 2026
Open
$24.03
From 52W high
−54.89%
Volume
2.49M
Market cap
$1.60B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.7x
P/E (TTM)
—
RSI (14)
35.8
MomentumView details →
1D Return
−3.52%
YTD Return
−7.88%
SummaryUpdated Jun 1, 2026
uniQure N.V. (NASDAQ:QURE) is a Dutch gene therapy company founded in 1998 and headquartered in Amsterdam, the Netherlands. The company went public on NASDAQ in February 2014. uniQure focuses on developing gene therapies for patients suffering from genetic and other devastating diseases, with a particular emphasis on rare neurological conditions and inherited disorders. The company has evolved from its early research phases to become a clinical-stage biotechnology firm with multiple programs advancing through various stages of human trials.
Similar companies
Latest newsMore news →
uniQure N.V. reported a third-quarter loss of $0.88 per share, compared with a loss of $1.38 per share a year earlier.8h agoThe DR REDDYS LABORATORIES LTD accepted uniQure N.V.'s Biologics License Application for investigational Huntington's disease gene therapy ifezuntirgene inilparvovec under the Accelerated Approval pathway.2d agoThe U.S. Food and Drug Administration accepted uniQure N.V.'s biologics license application for ifezuntirgene inilparvovec for Huntington's disease and granted it priority review, setting a PDUFA target action date of May 1, 2027.2d ago